Advertisement

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

Published:December 04, 2022DOI:https://doi.org/10.1016/j.jagp.2022.11.013

      Highlights

      • 1) What is the primary question addressed by this study?
        • This pilot open-label trial assessed the tolerability, safety, and potential clinical benefits of eight weeks of repeated intravenous (IV) ketamine infusions in geriatric treatment-resistant depression.
      • 2) What is the main finding of this study?
        • IV ketamine was well tolerated with no discontinuation due to adverse effects. Depressive symptoms and cognitive performance improved, with response in depression achieved in 48% of participants.
      • 3) What is the meaning of the finding?
        • The promising findings of this open pilot study of feasibility, tolerability, and clinical benefit of IV ketamine for TRD in older adults need to be confirmed and extended in a larger randomized controlled trial.

      ABSTRACT

      Objective

      Evidence-based treatment options for late-life treatment-resistant depression (TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of data on its safety and efficacy in older adults.

      Methods

      In this pilot clinical trial, 25 adults aged ≥60 years with TRD received IV ketamine openly twice a week for 4 weeks; partial responders at the end of this acute phase were eligible to receive weekly infusions for 4 more weeks in a continuation phase. Acceptability, tolerability, and safety, including adverse and serious adverse events (AEs and SAEs), blood pressure changes, dissociation, craving, in addition to rates of depression response and remission were evaluated. The NIH Toolbox Cognitive Battery was used to assess specific measures of executive function (EF) and overall fluid cognition.

      Results

      Completion rates were 88% for the acute phase and 100% for the continuation phase. No AEs resulted in participant discontinuation, and there were no SAEs. Treatment-emergent elevation of blood pressure, dissociation, and craving were transient and did not result in any participant discontinuation. Depressive symptoms improved significantly and 48% of participants responded. During the acute phase, the EF measures and the fluid cognition composite score improved (Cohen's d = 0.61), and these improvements were sustained in the continuation phase.

      Conclusion

      This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD. These promising findings need to be confirmed and extended in a larger randomized controlled trial.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Geriatric Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cristancho P
        • Lenard E
        • Lenze EJ
        • et al.
        Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): study design and treatment characteristics of the first 396 participants randomized.
        Am J Geriatr Psychiatry. 2019; 27: 1138-1152
        • Morimoto SS
        • Kanellopoulos D
        • Manning KJ
        • et al.
        Diagnosis and treatment of depression and cognitive impairment in late life.
        Ann N Y Acad Sci. 2015; 1345: 36-46
        • Lenze EJ
        • Mulsant BH
        • Blumberger DM
        • et al.
        Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2015; 386: 2404-2412
        • Wolkowitz OM
        • Reus VI
        • Mellon SH
        Of sound mind and body: depression, disease, and accelerated aging.
        Dialogues Clin Neurosci. 2011; 13: 25-39
        • Ownby RL
        • Crocco E
        • Acevedo A
        • et al.
        Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.
        Arch Gen Psychiatry. 2006; 63: 530-538
        • Byers AL
        • Yaffe K.
        Depression and risk of developing dementia.
        Nat Rev Neurol. 2011; 7: 323-331
        • Diniz BS
        • Butters MA
        • Albert SM
        • et al.
        Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies.
        Br J Psychiatry. 2013; 202: 329-335
        • Conelea CA
        • Philip NS
        • Yip AG
        • et al.
        Transcranial magnetic stimulation for treatment-resistant depression: naturalistic treatment outcomes for younger versus older patients.
        J Affect Disord. 2017; 217: 42-47
        • Kellner CH
        • Husain MM
        • Knapp RG
        • et al.
        Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study.
        Am J Psychiatry. 2016; 173: 1101-1109
        • Kellner CH
        • Husain MM
        • Knapp RG
        • et al.
        A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study.
        Am J Psychiatry. 2016; 173: 1110-1118
        • Lavretsky H
        • Lenze EJ
        • Karp JF
        • et al.
        Augementing vs. switching antidepressants for treatment resistant depression in older adults: results from the OPTIMUM study.
        in: Presented at the American College of Neuropsychopharmacology Symposium, Puerto Rico2021
        • Zarate Jr, CA
        • Singh JB
        • Carlson PJ
        • et al.
        A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
        Arch Gen Psychiatry. 2006; 63: 856-864
        • Wilkinson ST
        • Farmer C
        • Ballard ED
        • et al.
        Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
        Neuropsychopharmacology. 2019; 44: 1233-1238
        • Lenze EJ
        • Farber NB
        • Kharasch E
        • et al.
        Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial.
        World J Biol Psychiatry. 2016; 17: 230-238
        • Price RB
        • Iosifescu DV
        • Murrough JW
        • et al.
        Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
        Depress Anxiety. 2014; 31: 335-343
        • Moda-Sava RN
        • Murdock MH
        • Parekh PK
        • et al.
        Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
        (New York, N.Y.). 2019; 364 (eaat8078)
        • Singh JB
        • Fedgchin M
        • Daly EJ
        • et al.
        A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.
        Am J Psychiatry. 2016; 173: 816-826
        • Ke X
        • Ding Y
        • Xu K
        • et al.
        The profile of cognitive impairments in chronic ketamine users.
        Psychiatry Res. 2018; 266: 124-131
        • Morgan CJ
        • Muetzelfeldt L
        • Curran HV
        Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.
        Addiction. 2010; 105: 121-133
        • Cheng WJ
        • Chen CH
        • Chen CK
        • et al.
        Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia.
        Schizophr Res. 2018; 199: 313-318
        • Bryant KA
        • Altinay M
        • Finnegan N
        • et al.
        Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series.
        J Clin Psychopharmacol. 2019; 39: 158-161
        • Lipsitz O
        • Di Vincenzo JD
        • Rodrigues NB
        • et al.
        Safety, tolerability, and real-world effectiveness of intravenous ketamine in older adults with treatment-resistant depression: a case series.
        Am J Geriatr Psychiatry. 2021; 29: 899-913
        • George D
        • Galvez V
        • Martin D
        • et al.
        Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression.
        Am J Geriatr Psychiatry. 2017; 25: 1199-1209
        • Ross EL
        • Soeteman DI
        Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States.
        Psychiatr Serv. 2020; 71: 988-997
        • Lapidus KA
        • Levitch CF
        • Perez AM
        • et al.
        A randomized controlled trial of intranasal ketamine in major depressive disorder.
        Biol Psychiatry. 2014; 76: 970-976
        • Turner EH
        Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.
        Lancet Psychiatry. 2019; 6: 977-979
        • Zhang JC
        • Li SX
        • Hashimoto K.
        R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
        Pharmacol Biochem Behav. 2014; 116: 137-141
        • Zanos P
        • Moaddel R
        • Morris PJ
        • et al.
        Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms.
        Pharmacol Rev. 2018; 70: 621-660
        • Zanos P
        • Moaddel R
        • Morris PJ
        • et al.
        NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
        Nature. 2016; 533: 481-486
        • Yang C
        • Shirayama Y
        • Zhang JC
        • et al.
        R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
        Transl Psychiatry. 2015; 5: e632
        • Ochs-Ross R
        • Daly EJ
        • Zhang Y
        • et al.
        Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant Depression-TRANSFORM-3.
        Am J Geriatr Psychiatry. 2020; 28: 121-141
        • Ochs-Ross R
        • Wajs E
        • Daly EJ
        • et al.
        Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study.
        Am J Geriatr Psychiatry. 2022; 30: 541-556
        • Sackeim HA
        The definition and meaning of treatment-resistant depression.
        J Clin Psychiatry. 2001; 62: 10-17
        • Kroenke K
        • Spitzer RL
        • Williams JB.
        The PHQ-9: validity of a brief depression severity measure.
        J Gen Intern Med. 2001; 16: 606-613
        • Katzman R
        • Brown T
        • Fuld P
        • et al.
        Validation of a short Orientation-Memory-Concentration Test of cognitive impairment.
        Am J Psychiatry. 1983; 140: 734-739
        • Saunders JB
        • Aasland OG
        • Babor TF
        • et al.
        Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption—II.
        Addiction. 1993; 88: 791-804
        • Skinner HA.
        The drug abuse screening test.
        Addict Behav. 1982; 7: 363-371
        • Montgomery SA
        • Asberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Bremner JD
        • Krystal JH
        • Putnam FW
        • et al.
        Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).
        J Trauma Stress. 1998; 11: 125-136
        • Weintraub S
        • Dikmen SS
        • Heaton RK
        • et al.
        Cognition assessment using the NIH Toolbox.
        Neurology. 2013; 80: S54-S64
        • Rodrigues NB
        • McIntyre RS
        • Lipsitz O
        • et al.
        Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
        Expert Opin Drug Saf. 2020; 19: 1031-1040
        • Wan LB
        • Levitch CF
        • Perez AM
        • et al.
        Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
        J Clin Psychiatry. 2015; 76: 247-252
        • Gill H
        • Gill B
        • Rodrigues NB
        • et al.
        The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research.
        Neurosci Biobehav Rev. 2021; 120: 78-85